The limited number of studies investigating ADAM17 in NSCLC has suggested that elevated ADAM17 expression correlates with numerous clinicopathological characteristics (e.g., tumor grade) and poor survival (Ni et al, 2013). Here, ADAM17 is linked to neoplasm.